High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

2.

Weeks

L

,

Niroula

A

,

Neuberg

DS

, et al.

Prediction of risk for myeloid malignancy in clonal hematopoiesis

.

NEJM Evid

.

2022

;

140

(

suppl 1

):

2229

-

2231

.

3.

Xie

Z

,

Komrokji

RS

,

Al-Ali

N

, et al.

Risk prediction for clonal cytopenia: multicenter real-world evidence

.

Blood

.

2024

;

144

(

19

):

2033

-

2044

.

4.

Li

M

,

Binder

M

,

Lasho

T

, et al.

Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients

.

Blood Adv

.

2021

;

5

(

8

):

2272

-

2278

.

5.

Xie

Z

,

Nanaa

A

,

Saliba

A

, et al.

Treatment outcome for symptomatic patients with clonal cytopenia of undetermined significance: a single-institution retrospective study [abstract]

.

Blood Cancer J

.

2021

;

11

(

3

):

43

.

6.

Shenoy

N

,

Creagan

E

,

Witzig

T

,

Levine

M

.

Ascorbic acid in cancer treatment: let the phoenix fly

.

Cancer Cell

.

2018

;

34

(

5

):

700

-

706

.

7.

Agathocleous

M

,

Meacham

CE

,

Burgess

RJ

, et al.

Ascorbate regulates haematopoietic stem cell function and leukaemogenesis

.

Nature

.

2017

;

549

(

7673

):

476

-

481

.

8.

Levine

M

,

Padayatty

SJ

,

Espey

MG

,

Vitamin

C

.

A concentration-function approach yields pharmacology and therapeutic discoveries

.

Adv Nutr

.

2011

;

2

(

2

):

78

-

88

.

9.

Ko

M

,

Huang

Y

,

Jankowska

AM

, et al.

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

.

Nature

.

2010

;

468

(

7325

):

839

-

843

.

10.

Das

AB

,

Smith-Díaz

CC

,

Vissers

MCM

.

Emerging epigenetic therapeutics for myeloid leukemia: modulating demethylase activity with ascorbate

.

Haematologica

.

2021

;

106

(

1

):

14

-

25

.

11.

Cimmino

L

,

Dolgalev

I

,

Wang

Y

, et al.

Restoration of TET2 function blocks aberrant self-renewal and leukemia progression

.

Cell

.

2017

;

170

(

6

):

1079

-

1095.e20

.

12.

Platzbecker

U

,

Fenaux

P

,

Adès

L

, et al.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

.

Blood

.

2019

;

133

(

10

):

1020

-

1030

.

13.

Arber

DA

,

Orazi

A

,

Hasserjian

R

, et al.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

.

Blood

.

2016

;

127

(

20

):

2391

-

2405

.

14.

Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. US Department of Health and Human Services; 2009

. Accessed 14 June 2010. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.

15.

Behnert

A

,

Meyer

J

,

Parsa

JY

, et al.

Genetic alterations precede DNA methylation changes in juvenile myelomonocytic leukemia [abstract]

.

Blood

.

2020

;

136

(

suppl 1

):

19

-

20

.

16.

Cull

AH

,

Snetsinger

B

,

Buckstein

R

,

Wells

RA

,

Rauh

MJ

.

Tet2 restrains inflammatory gene expression in macrophages

.

Exp Hematol

.

2017

;

55

:

56

-

70.e13

.

17.

Selimoglu-Buet

D

,

Wagner-Ballon

O

,

Saada

V

, et al.

Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia

.

Blood

.

2015

;

125

(

23

):

3618

-

3626

.

18.

Loghavi

S

,

Kanagal-Shamanna

R

,

Khoury

JD

, et al.

5th edition of the World Health Classification of tumors of the hematopoietic and lymphoid tissues

.

Mod Pathol

.

2024

;

37

(

2

):

100397

.

19.

Urivetzky

M

,

Kessaris

D

,

Smith

AD

.

Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis

.

J Urol

.

1992

;

147

(

5

):

1215

-

1218

.

20.

Roadmap Epigenomics Consortium

,

Kundaje

A

,

Meuleman

W

, et al.

Integrative analysis of 111 reference human epigenomes

.

Nature

.

2015

;

518

(

7539

):

317

-

330

.

21.

Taira

A

,

Palin

K

,

Kuosmanen

A

, et al.

Vitamin C boosts DNA demethylation in TET2 germline mutation carriers

.

Clin Epigenetics

.

2023

;

15

(

1

):

7

-

13

.

22.

Hammal

F

,

De Langen

P

,

Bergon

A

,

Lopez

F

,

Ballester

B

.

ReMap 2022: a database of human, mouse, drosophila and arabidopsis regulatory regions from an integrative analysis of DNA-binding sequencing experiments

.

Nucleic Acids Res

.

2022

;

50

(

D1

):

D316

-

D325

.

23.

Chondrou

V

,

Markopoulos

GS

,

Patrinos

GP

, et al.

LRF/ZBTB7A conservation accentuates its potential as a therapeutic target for the hematopoietic disorders

.

Gene X

.

2020

;

760

:

145020

.

24.

Dey

A

,

Yang

W

,

Gegonne

A

, et al.

BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses

.

EMBO J

.

2019

;

38

(

7

):

e100293

.

25.

Gillberg

L

,

Ørskov

AD

,

Nasif

A

, et al.

Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: normalization of plasma vitamin C induces epigenetic changes

.

Clin Epigenetics

.

2019

;

11

(

1

):

143

. 11.